Completed OBSERVATIONAL NCT03880643

Rituximab in Refractory Primary Membranous Nephropathy

Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy

Sponsor: Istanbul University

Conditions Glomerulonephritis, Membranous

Updated 7 times since 2019 Last updated: Nov 8, 2019 Started: Nov 1, 2018 Primary completion: May 31, 2019 Completion: Sep 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03880643, this observational or N/A phase trial focuses on Glomerulonephritis, Membranous and remains completed. Sponsored by Istanbul University, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Dec 2019 — Jan 2021 [monthly]

Completed

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Aug 2019 — Dec 2019 [monthly]

Active Not Recruiting
Apr 2019 — Aug 2019 [monthly]

Active Not Recruiting

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istanbul University

Data source: Istanbul University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Istanbul, Turkey (Türkiye)